• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'

2

Former VP Kamala Harris says she went through a nine-hour interview to land the job—but she couldn’t escape ‘gold medal depression’ even when she won

3

NBC’s Tom Llamas climbed from 15-year-old intern to the top anchor chair—and still isn’t satisfied: ‘If you're not growing, you're dying'

1

Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'

2

Former VP Kamala Harris says she went through a nine-hour interview to land the job—but she couldn’t escape ‘gold medal depression’ even when she won

3

NBC’s Tom Llamas climbed from 15-year-old intern to the top anchor chair—and still isn’t satisfied: ‘If you're not growing, you're dying'
LeadershipMarijuana

Orrin Hatch’s Medical Marijuana Announcement Is a Masterpiece of Weed Puns

By
Kirsten Korosec
Kirsten Korosec
Down Arrow Button Icon
By
Kirsten Korosec
Kirsten Korosec
Down Arrow Button Icon
September 13, 2017, 3:25 PM ET
Add Fortune on Google for similar content.

Utah Senator Orrin Hatch introduced a Senate bill on Wednesday that would make it easier to research the potential medical benefits of marijuana and whether it’s a safe and effective alternative to opioids.

The bill, known as the Marijuana Effective Drug Study Act of 2017, or MEDS Act, is being introduced at a time when the U.S. is grappling with an opioid crisis that has caused teen overdose deaths rates to spike, a significant drop in U.S. labor force participation—particularly among American men, and has prompted President Trump to declare it a national emergency.

Hatch, who is Mormon, is still opposed to recreational use of marijuana. But he noted, in prepared remarks filled with marijuana-related puns, that it’s time to remove barriers preventing legitimate research into medical marijuana.

It’s high time to address research into medical marijuana. Our country has experimented with a variety of state solutions without properly delving into the weeds on the effectiveness, safety, dosing, administration, and quality of medical marijuana. All the while, the federal government strains to enforce regulations that sometimes do more harm than good. To be blunt, we need to remove the administrative barriers preventing legitimate research into medical marijuana, which is why I’ve decided to roll out the MEDS Act.

The bill, hopes to encourage research in potential medical uses of marijuana by streamlining the research registration process and make marijuana more available for scientific and medical research and the commercial production of any FDA-approved drugs derived from marijuana. If passed, the U.S. Attorney General would be required increase the national marijuana quota in a timely manner to meet the changing medical, scientific, and industrial needs for marijuana.

The bill would include protections to ensure controlled marijuana substances are not abused, according to Hatch’s office. National Institute on Drug Abuse would be required to develop and publish recommendations for good manufacturing practices for growing and producing marijuana for research.

Here’s an excerpt of the speech he is expected to deliver on the Senate floor at 3:30 p.m. ET:

It will surprise no one that I am strongly against the use of recreational marijuana. I worry, however, that in our zeal to enforce the law, we too often blind ourselves to the medicinal benefits of natural substances like cannabis. While I certainly do not support the use of marijuana for recreational purposes, the evidence shows that cannabis possesses medicinal properties that can truly change people’s lives for the better. And I believe, Mr. President, that we would be remiss if we threw out the baby with the bathwater.
We lack the science to support use of medical marijuana products like CBD oils not because researchers are unwilling to do the work, but because of bureaucratic red tape and over-regulation. Under current law, those who want to complete research on the benefits of medical marijuana must engage in a complex application process and interact with several federal agencies. These regulatory acrobatics can take researchers over a year, if not more, to complete. And the longer researchers have to wait, the longer patients have to suffer.
Senators Schatz (D-HI). Chris Coons (D-DE), Cory Gardner (R-CO), and Thom Tillis (R-NC) are co-sponsors of the bill. There are other marijuana medical research bills that have been introduced to the Senate this year, including the Compassionate Access, Research Expansion and Respect States, or CARERS Act by Senators Rand Paul (R-Kentucky), Corey Booker (D-New Jersey) and Kirsten Gillibrand (D-New York).
About the Author
By Kirsten Korosec
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Leadership

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Leadership

Sony industry starmaker Clive Davis, who launched the careers of Janis Joplin and Whitney Houston, dead at 94
Arts & EntertainmentMusic
Sony industry starmaker Clive Davis, who launched the careers of Janis Joplin and Whitney Houston, dead at 94
By The Associated Press, Mark Sherman and NEKESA MUMBI MOODYJune 22, 2026
1 hour ago
Elon Musk to get a billion shares of SpaceX if he can settle a million humans on Mars
Startups & VentureElon Musk
Elon Musk to get a billion shares of SpaceX if he can settle a million humans on Mars
By Catherina GioinoJune 22, 2026
2 hours ago
America has a $4 trillion retirement crisis and half of workers could run out of money. TIAA’s CEO wants ‘guaranteed lifetime income’ to fix it
C-SuiteFortune 500: Titans and Disruptors of Industry
America has a $4 trillion retirement crisis and half of workers could run out of money. TIAA’s CEO wants ‘guaranteed lifetime income’ to fix it
By Fortune EditorsJune 22, 2026
2 hours ago
Thibault Sottiaux, Head of Core Product and Platform OpenAI, speaking.
AIOpenAI
OpenAI’s new ‘super app’ boss hopes to persuade users and potential IPO investors that the company is about way more than just chat
By Beatrice NolanJune 22, 2026
3 hours ago
Reassuring dad sits with frustrated adult son
SuccessCost of living
1 in 3 young adults were still living with their parents in 2025—that’s more than the during pandemic and they’re not even unemployed
By Emma BurleighJune 22, 2026
3 hours ago
Brian Moynihan
SuccessProductivity
By 7 a.m., Bank of America’s CEO has already read 5 newspapers, his email inbox, and hit the gym—he says if you’re late to meetings, you’re ‘selfish’
By Preston ForeJune 22, 2026
3 hours ago

Most Popular

Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'
Success
Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'
By Sydney LakeJune 21, 2026
1 day ago
Former VP Kamala Harris says she went through a nine-hour interview to land the job—but she couldn’t escape ‘gold medal depression’ even when she won
Success
Former VP Kamala Harris says she went through a nine-hour interview to land the job—but she couldn’t escape ‘gold medal depression’ even when she won
By Emma BurleighJune 21, 2026
1 day ago
NBC’s Tom Llamas climbed from 15-year-old intern to the top anchor chair—and still isn’t satisfied: ‘If you're not growing, you're dying'
Success
NBC’s Tom Llamas climbed from 15-year-old intern to the top anchor chair—and still isn’t satisfied: ‘If you're not growing, you're dying'
By Preston ForeJune 21, 2026
1 day ago
'I literally was crying last night because I’m nervous about what I’m going to find out': a record 51% of Americans aren't 'cost secure' on health
Health
'I literally was crying last night because I’m nervous about what I’m going to find out': a record 51% of Americans aren't 'cost secure' on health
By Ali Swenson, Amelia Thomson-Deveaux and The Associated PressJune 20, 2026
2 days ago
Tenzin Seldon: The GLP-1 boom is the biggest climate story no one is pricing in
Commentary
Tenzin Seldon: The GLP-1 boom is the biggest climate story no one is pricing in
By Tenzin SeldonJune 21, 2026
1 day ago
Ezekiel Emanuel: My father lived into his 90s. He understood something many successful men miss
Commentary
Ezekiel Emanuel: My father lived into his 90s. He understood something many successful men miss
By Ezekiel J. EmanuelJune 21, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.